Patents Examined by Michael J Schmitt
-
Patent number: 12036220Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.Type: GrantFiled: April 3, 2023Date of Patent: July 16, 2024Assignee: Mind Medicine, Inc.Inventors: Peter Mack, Timm Trenktrog, Dustin Melton, Bethany Amber Doty, Jon Schroeder, Lisa Marie Garrett
-
Patent number: 12029712Abstract: This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.Type: GrantFiled: May 27, 2020Date of Patent: July 9, 2024Assignee: Sun Pharmaceutical Industries, Inc.Inventors: Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
-
Patent number: 11999676Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.Type: GrantFiled: April 14, 2020Date of Patent: June 4, 2024Assignee: University of Kentucky Research FoundationInventors: Linda P. Dwoskin, David Watt, Jon Thorson, Mark Leggas, Kip Guy, Jared Hammill, Stefan Kwiatkowski, Derong Ding, Guangrong Zheng, Peter Anthony Crooks, Na-Ra Lee
-
Patent number: 11999724Abstract: The present invention relates to a novel method for producing diarylpyridine derivatives, and the object of the present invention is to provide a novel, industrially useful method. The present inventors developed a novel method for synthesizing pyridine rings without using palladium, a strong base, or a high-temperature reaction. In particular, they successfully developed a method that can be used to synthesize iminium salts as intermediates, synthesize cyano compounds from these iminium salts, and cyclize the cyano compounds into pyridines under very mild reaction conditions.Type: GrantFiled: July 3, 2019Date of Patent: June 4, 2024Assignee: Daiichi Sankyo Company, LimitedInventors: Yuichi Aki, Fumihiko Toriyama, Natsuki Sakurai, Ai Kameda, Tomokazu Ogura
-
Patent number: 11998519Abstract: Compositions and methods are presented that, upon administration prior to trauma, are effective to prevent and/or reduce severity of sequelae of TBI upon trauma. Advantageously, the compositions presented herein can be orally administered, have an excellent safety profile, and will not require a prescription by physician or hospital admission.Type: GrantFiled: March 16, 2022Date of Patent: June 4, 2024Inventor: Rob D. Dickerman
-
Patent number: 11986454Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: June 22, 2023Date of Patent: May 21, 2024Assignee: AXSOME MALTA LTD.Inventor: Katayoun Zomorodi
-
Patent number: 11986455Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: April 3, 2023Date of Patent: May 21, 2024Assignee: AXSOME MALTA LTD.Inventor: Katayoun Zomorodi
-
Patent number: 11975009Abstract: The present disclosure provides for a method of inhibiting the growth of a microorganism including contacting the microorganism with zinc porphyrin (ZnPor). The present disclosure also provides for a method of treating or preventing biofilm formation of one or more microorganisms including contacting the biofilm with zinc porphyrin (ZnPor). Further, the present disclosure provides for a method of treating a disease associated with biofilm formation in a subject including administering to the subject a composition comprising a therapeutically effective amount of ZnPor.Type: GrantFiled: May 2, 2022Date of Patent: May 7, 2024Assignee: ZNABLE LLCInventor: Jayne Robinson
-
Patent number: 11969404Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: April 3, 2023Date of Patent: April 30, 2024Assignee: AXSOME MALTA LTD.Inventor: Katayoun Zomorodi
-
Patent number: 11964987Abstract: The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists.Type: GrantFiled: September 22, 2020Date of Patent: April 23, 2024Assignee: Rutgers, The State University of New JerseyInventor: Achyutharao Sidduri
-
Patent number: 11944631Abstract: Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer.Type: GrantFiled: August 2, 2021Date of Patent: April 2, 2024Assignee: Infinity Pharmaceuticals, Inc.Inventors: Jeffery L Kutok, Howard M. Stern
-
Patent number: 11944607Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).Type: GrantFiled: July 2, 2021Date of Patent: April 2, 2024Assignee: MediciNova, Inc.Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
-
Patent number: 11944629Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml.Type: GrantFiled: February 25, 2020Date of Patent: April 2, 2024Assignee: MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARARATE MBHInventor: Heiner Will
-
Patent number: 11925633Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.Type: GrantFiled: December 18, 2020Date of Patent: March 12, 2024Assignee: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Tadamasa Matsumoto, Masafumi Ihara, Satoshi Saito, Masanori Fukushima
-
Patent number: 11918586Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituType: GrantFiled: March 26, 2021Date of Patent: March 5, 2024Assignees: TORQUR AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Doriano Fabbro, Paul Hebeisen, Petra Hillmann-Wuellner, Anton Stuetz, John T. Seykora, Florent Beaufils
-
Patent number: 11911360Abstract: The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.Type: GrantFiled: January 27, 2021Date of Patent: February 27, 2024Assignee: Lachesis Biosciences LimitedInventor: Timothy Matthias Morgan
-
Patent number: 11911377Abstract: The present disclosure provides a method for treating hypertension by using a compound, wherein the compound is selected from the group consisting of: (E)-4-(3-(3-methyl benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (2R)-2-amino-3-(2,3-dihydro-1H-inden-1-yl)-N?-((E)-quinolin-7-ylmethylene)propane hydrazide, and a combination thereof. The present disclosure uses a small molecule compound (E)-4-(3-(3-methyl benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (2R)-2-amino-3-(2,3-dihydro-1H-inden-1-yl)-N?-((E)-quinolin-7-ylmethylene)propane hydrazide or a combination thereof, which can be developed as a therapeutic drug for lowering blood pressure, whether it is taken orally or injected.Type: GrantFiled: November 3, 2021Date of Patent: February 27, 2024Assignee: FU JEN CATHOLIC UNIVERSITYInventors: Fu-Tien Chiang, Wei-Chao Chiu
-
Patent number: 11896710Abstract: The present disclosure provides methods of treating inflammation of the upper gastrointestinal tract, especially the esophagus, by administering an oral corticosteroid. In some cases, the methods include treating eosinophilic esophagitis (EoE) by administering an oral corticosteroid in an induction phase and a maintenance phase to improve peak eosinophilic counts and symptoms. In embodiments, the methods include treating EoE by administering the oral corticosteroid at nighttime and/or while the patient is lying down.Type: GrantFiled: July 15, 2021Date of Patent: February 13, 2024Assignee: Ellodi Pharmaceuticals, L.P.Inventors: Brian A. Meltzer, Gail M. Comer
-
Patent number: 11859252Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).Type: GrantFiled: September 7, 2018Date of Patent: January 2, 2024Assignee: Genentech, Inc.Inventors: Christiaan Nicolaas Klijn, Shiva Malek, Ivana Yen
-
Patent number: 11850228Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: April 3, 2023Date of Patent: December 26, 2023Assignee: Axsome Malta Ltd.Inventor: Katayoun Zomorodi